Cargando…

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology

In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and their actual benefit for patients. By adopting “pleural mesothelioma” as our clinical model we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meirson, Tomer, Nardone, Valerio, Pentimalli, Francesca, Markel, Gal, Bomze, David, D’Apolito, Maria, Correale, Pierpaolo, Giordano, Antonio, Pirtoli, Luigi, Porta, Camillo, Gray, Steven G, Mutti, Luciano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749371/ https://www.ncbi.nlm.nih.gov/pubmed/36514092 http://dx.doi.org/10.1186/s12967-022-03744-6

Ejemplares similares

Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
por: Meirson, Tomer, et al.
Publicado: (2022)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020)

Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect
por: Horesh, Nir, et al.
Publicado: (2022)

Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer
por: Meirson, Tomer, et al.
Publicado: (2023)

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
por: Nardone, Valerio, et al.
Publicado: (2023)

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy
por: Correale, Pierpaolo, et al.
Publicado: (2020)

How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies
por: Nardone, Valerio, et al.
Publicado: (2018)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
por: Nardone, Valerio, et al.
Publicado: (2021)

Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
por: Mutti, Luciano, et al.
Publicado: (2020)

Trends in Women’s Leadership of Oncology Clinical Trials
por: Waldhorn, Ithai, et al.
Publicado: (2022)

Is There Already a Need of Reckoning on Cancer Immunotherapy?
por: Correale, Pierpaolo, et al.
Publicado: (2021)

A Glimpse in the Future of Malignant Mesothelioma Treatment
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
por: Morani, Federica, et al.
Publicado: (2021)

Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
por: Pentimalli, Francesca, et al.
Publicado: (2023)

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2022)

Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade
por: Indovina, Paola, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo
por: Miluzio, Annarita, et al.
Publicado: (2015)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
por: Tenti, Sara, et al.
Publicado: (2020)

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
por: Asher, Nethanel, et al.
Publicado: (2021)

MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study
por: Mozzoni, Paola, et al.
Publicado: (2017)

Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation
por: Nardone, Valerio, et al.
Publicado: (2019)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1e4arfji2drr4g17vqhhua29t6